Cancer clinical trials in the region Grand Est
296 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Colon cancer
Rectal cancer
#NCT05253651
#2024-514180-25-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
KRAS G12C
KRAS non G12C
NRAS
17 recruiting sites
Seagen
Phase 3
Lung cancer
#NCT06216301
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
MET
NTRK-1/2/3
RET
ROS-1
8 recruiting sites
NovoCure GmbH
Phase 2 / Phase 3
Endometrial cancer
#NCT03651206
#2024-516782-36-00
Required histologic sub types
Carcinosarcoma
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Immunotherapy
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Immunotherapy
Targeted therapy
16 recruiting sites
ARCAGY/ GINECO GROUP
Phase 2 / Phase 3
Bladder / Urinary Tract / Urethral cancer
#NCT07129993
#2024-516906-47-00
Required histologic types
Invasive bladder cancer
Upper excretory tract cancer
Urethral cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
15 recruiting sites
Daiichi Sankyo
Phase 2 / Phase 3
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Pancreas cancer
Stomach and esophageal cancer
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT06943755
#2025-521043-20-00
Required histologic sub types
Neuroendocrine tumor
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
11 recruiting sites
Exélixis
Phase 2 / Phase 3
Lung cancer
#NCT07063745
#2025-521511-40-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required genetic anomalies
MTAP
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Targeted therapy
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
16 recruiting sites
Bristol-Myers Squibb
Phase 2 / Phase 3
Head and neck cancer
#NCT06788990
#2024-519654-37-00
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required HPV statuses
HPV Negative
Required CPS scores
CPS Positive (1 <= X < 20)
CPS Positive (X >= 20)
12 recruiting sites
Bicara Therapeutics
Phase 2 / Phase 3
Bladder / Urinary Tract / Urethral cancer
#NCT07106762
#2025-522400-24-00
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
Antibody Drug Conjugates (ADC)
10 recruiting sites
Bristol-Myers Squibb
Phase 2 / Phase 3
Colon cancer
Rectal cancer
#NCT05462613
#2024-516709-22-00
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Surgery
Chemotherapy
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
11 recruiting sites
CHU de Besançon
Phase 2
Lung cancer
#NCT06712316
#2024-515764-31-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
Excluded previous treatments at localized stage
Immunotherapy
Chemotherapy
Targeted therapy
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Targeted therapy
Bispecific T-cell engager antibodies
24 recruiting sites
BioNTech SE